by Combat Cancer | Aug 16, 2025 | News
Non–muscle–invasive bladder cancer (NMIBC) presents a significant therapeutic challenge. Nearly 70% of NMIBC cases recur, and a considerable subset progress to muscle invasion, requiring radical cystectomy – a procedure which many patients either refuse or...
by Combat Cancer | Aug 9, 2025 | News
Intravesical Bacillus Calmette‑Guérin (BCG) following transurethral resection of bladder tumour (TURBT) remains the primary treatment strategy for intermediate‑ and high‑risk non‑muscle‑invasive bladder cancer (NMIBC). Nevertheless, around four in ten patients...
by Combat Cancer | Aug 1, 2025 | News
In pancreatic ductal adenocarcinoma (PDAC), the most common and deadliest form of pancreatic cancer, pancreatic cancer cells drastically reprogram nearby normal fibroblasts – cells that normally maintain tissue structure and repair – to become...
by Combat Cancer | Jul 26, 2025 | News
A new study released on 18th July 2025 in “Frontiers in Endocrinology” has revealed that the gene SDR42E1 is key to the absorption and metabolism of vitamin D – and when inactivated in colorectal cancer cells, can drastically reduce their survival....
by Combat Cancer | Jul 19, 2025 | News
Bladder cancer is one of the most common cancers worldwide, but what many people don’t realise is that it’s not a single, uniform disease. Among the various types, histologic variant (HV) bladder cancers stand out as especially rare, aggressive, and...
Recent Comments